Overview

Chemomab is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.

Chemomab is currently promoting in parallel three phase 2 studies, focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Recent News
May 24, 2023

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases...

May 11, 2023

─Reported Top-line Results from CM-101 Phase 2 Liver Fibrosis Trial in NASH Patients Demonstrating Safety and Positive Activity Across Multiple Fibrotic and Inflammatory Biomarkers─...

Apr 26, 2023

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases...

Apr 19, 2023

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases...

All News

Stock Info
NASDAQCMMB
Events
Friday, May 12, 2023
5:20pm - 5:50pm CEST

Venue:Grand Hotel Baglioni, Florence, Italy
Format: Poster presentation: Patient proteomic data and mouse model reinforce the proinflammatory role of CCL24 in cholestatic disease
Session: ePoster session 3 and break
Presenter: Matt Frankel, MD, Chief Medical Officer, Chemomab
Information: https://easl.eu/event/biliary-fibrosis-23/

Thursday, May 11, 2023
8:00am - 9:00am EDT

Live Webcast and Conference Call at 8:00 am Eastern Time, Thursday, May 11, 2023

Click this Webcast link to access the live webcast or replay.

The live webcast and replay can also be accessed at the News & Events section of the Investors page on the Chemomab website at investors.chemomab.com/events.  

Conference Call Access via Telephone

  • US Investors: +1 (877) 407-9208
  • International Investors: +1 (201) 493-6784
  • Conference ID code: 13735393

Please call 5-10 minutes before the scheduled start time, enter the conference passcode and ask the operator for the Chemomab conference call.

Or click on Call me™ starting 15 minutes before the scheduled start time for instant telephone access without having to wait for an operator.

All Events

Featured Presentations

Download

Chemomab Corporate Overview - May 2023

 

Annual Report

Download

Chemomab 2021 Annual Report